These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 26048091)

  • 1. Important species differences regarding lymph contribution to gut hormone responses.
    Hansen M; Hjøllund KR; Hartmann B; Plamboeck A; Deacon CF; Wewer Albrechtsen NJ; Holst JJ
    Peptides; 2015 Sep; 71():28-31. PubMed ID: 26048091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog.
    Edgerton DS; Johnson KM; Neal DW; Scott M; Hobbs CH; Zhang X; Duttaroy A; Cherrington AD
    Diabetes; 2009 Jan; 58(1):243-9. PubMed ID: 18840785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.
    Ahrén B; Schweizer A; Dejager S; Villhauer EB; Dunning BE; Foley JE
    Diabetes Obes Metab; 2011 Sep; 13(9):775-83. PubMed ID: 21507182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs.
    Hjøllund KR; Deacon CF; Holst JJ
    Diabetologia; 2011 Aug; 54(8):2206-8. PubMed ID: 21604085
    [No Abstract]   [Full Text] [Related]  

  • 5. Suppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4.
    Jessen L; Aulinger BA; Hassel JL; Roy KJ; Smith EP; Greer TM; Woods SC; Seeley RJ; D'Alessio DA
    Endocrinology; 2012 Dec; 153(12):5735-45. PubMed ID: 23033273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of vildagliptin in the management of type 2 diabetes mellitus.
    Kleppinger EL; Helms K
    Ann Pharmacother; 2007 May; 41(5):824-32. PubMed ID: 17456545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes.
    Akarte AS; Srinivasan BP; Gandhi S
    J Diabetes Complications; 2012; 26(4):266-74. PubMed ID: 22626875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl peptidase-4 greatly contributes to the hydrolysis of vildagliptin in human liver.
    Asakura M; Fujii H; Atsuda K; Itoh T; Fujiwara R
    Drug Metab Dispos; 2015 Apr; 43(4):477-84. PubMed ID: 25597851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vildagliptin stimulates endothelial cell network formation and ischemia-induced revascularization via an endothelial nitric-oxide synthase-dependent mechanism.
    Ishii M; Shibata R; Kondo K; Kambara T; Shimizu Y; Tanigawa T; Bando YK; Nishimura M; Ouchi N; Murohara T
    J Biol Chem; 2014 Sep; 289(39):27235-27245. PubMed ID: 25100725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
    Thornberry NA; Gallwitz B
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-cell expression of a dominant-negative HNF-1alpha compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice.
    Ahrén B; Sörhede Winzell M; Burkey B; Hughes TE
    Eur J Pharmacol; 2005 Oct; 521(1-3):164-8. PubMed ID: 16171801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats.
    Burkey BF; Li X; Bolognese L; Balkan B; Mone M; Russell M; Hughes TE; Wang PR
    J Pharmacol Exp Ther; 2005 Nov; 315(2):688-95. PubMed ID: 16027230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition.
    Chang E; Kim L; Choi JM; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Park DI; Park CY
    Metabolism; 2015 May; 64(5):633-41. PubMed ID: 25704082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal lymph as a readout of meal-induced GLP-1 release in an unrestrained rat model.
    Jejelava N; Kaufman S; Krieger JP; Terra MM; Langhans W; Arnold M
    Am J Physiol Regul Integr Comp Physiol; 2018 May; 314(5):R724-R733. PubMed ID: 29341824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
    Akarte AS; Srinivasan BP; Gandhi S
    Biochem Pharmacol; 2012 Jan; 83(2):241-52. PubMed ID: 22015634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide.
    Ahrén B; Winzell MS; Wierup N; Sundler F; Burkey B; Hughes TE
    Regul Pept; 2007 Oct; 143(1-3):97-103. PubMed ID: 17482289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients.
    Boschmann M; Engeli S; Dobberstein K; Budziarek P; Strauss A; Boehnke J; Sweep FC; Luft FC; He Y; Foley JE; Jordan J
    J Clin Endocrinol Metab; 2009 Mar; 94(3):846-52. PubMed ID: 19088168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between anagliptin concentration showing over 80% inhibition of plasma dipeptidyl peptidase-4 activity and its protective effect against glucagon-like peptide-1 degradation.
    Furuta S; Goto M; Tamura M; Yamashita S; Nakaya K; Furuta Y
    Drug Res (Stuttg); 2014 Mar; 64(3):130-5. PubMed ID: 23965798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLP-1 signalling compensates for impaired insulin signalling in regulating beta cell proliferation in βIRKO mice.
    Kawamori D; Shirakawa J; Liew CW; Hu J; Morioka T; Duttaroy A; Burkey B; Kulkarni RN
    Diabetologia; 2017 Aug; 60(8):1442-1453. PubMed ID: 28526921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.
    Hansen L; Deacon CF; Orskov C; Holst JJ
    Endocrinology; 1999 Nov; 140(11):5356-63. PubMed ID: 10537167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.